190 related articles for article (PubMed ID: 30470974)
1. Targeting tyrosine kinases for treatment of ocular tumors.
Jo DH; Kim JH; Kim JH
Arch Pharm Res; 2019 Apr; 42(4):305-318. PubMed ID: 30470974
[TBL] [Abstract][Full Text] [Related]
2. Metastatic uveal melanoma: biology and emerging treatments.
Woodman SE
Cancer J; 2012; 18(2):148-52. PubMed ID: 22453016
[TBL] [Abstract][Full Text] [Related]
3. Imatinib mesylate alters the expression of genes related to disease progression in an animal model of uveal melanoma.
Fernandes BF; Di Cesare S; Neto Belfort R; Maloney S; Martins C; Castiglione E; Isenberg J; Abourbih D; Antecka E; Burnier MN
Anal Cell Pathol (Amst); 2011; 34(3):123-30. PubMed ID: 21606571
[TBL] [Abstract][Full Text] [Related]
4. Targeted therapy for uveal melanoma.
Triozzi PL; Eng C; Singh AD
Cancer Treat Rev; 2008 May; 34(3):247-58. PubMed ID: 18226859
[TBL] [Abstract][Full Text] [Related]
5. Uveal melanoma.
Spagnolo F; Caltabiano G; Queirolo P
Cancer Treat Rev; 2012 Aug; 38(5):549-53. PubMed ID: 22270078
[TBL] [Abstract][Full Text] [Related]
6. New therapeutic agents in uveal melanoma.
Velho TR; Kapiteijn E; Jager MJ
Anticancer Res; 2012 Jul; 32(7):2591-8. PubMed ID: 22753717
[TBL] [Abstract][Full Text] [Related]
7. The Role of Histone Deacetylase Inhibitors in Uveal Melanoma: Current Evidence.
Moschos MM; Dettoraki M; Androudi S; Kalogeropoulos D; Lavaris A; Garmpis N; Damaskos C; Garmpi A; Tsatsos M
Anticancer Res; 2018 Jul; 38(7):3817-3824. PubMed ID: 29970501
[TBL] [Abstract][Full Text] [Related]
8. Expression patterns of cyclin D1 and related proteins regulating G1-S phase transition in uveal melanoma and retinoblastoma.
Coupland SE; Bechrakis N; Schüler A; Anagnostopoulos I; Hummel M; Bornfeld N; Stein H
Br J Ophthalmol; 1998 Aug; 82(8):961-70. PubMed ID: 9828785
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo anti-uveal melanoma activity of JSL-1, a novel HDAC inhibitor.
Wang Y; Liu M; Jin Y; Jiang S; Pan J
Cancer Lett; 2017 Aug; 400():47-60. PubMed ID: 28455241
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of NF-κB-Dependent Signaling Enhances Sensitivity and Overcomes Resistance to BET Inhibition in Uveal Melanoma.
Ambrosini G; Do C; Tycko B; Realubit RB; Karan C; Musi E; Carvajal RD; Chua V; Aplin AE; Schwartz GK
Cancer Res; 2019 May; 79(9):2415-2425. PubMed ID: 30885979
[TBL] [Abstract][Full Text] [Related]
11. Novel therapeutic strategies and targets in advanced uveal melanoma.
Chua V; Aplin AE
Curr Opin Oncol; 2018 Mar; 30(2):134-141. PubMed ID: 29206651
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic implications of the emerging molecular biology of uveal melanoma.
Patel M; Smyth E; Chapman PB; Wolchok JD; Schwartz GK; Abramson DH; Carvajal RD
Clin Cancer Res; 2011 Apr; 17(8):2087-100. PubMed ID: 21444680
[TBL] [Abstract][Full Text] [Related]
13. Experimental therapy of doxorubicin resistant human uveal melanoma with targeted cytotoxic luteinizing hormone-releasing hormone analog (AN-152).
Oláh G; Dobos N; Vámosi G; Szabó Z; Sipos É; Fodor K; Harda K; Schally AV; Halmos G
Eur J Pharm Sci; 2018 Oct; 123():371-376. PubMed ID: 30076951
[TBL] [Abstract][Full Text] [Related]
14. Current Molecularly Targeting Therapies in NSCLC and Melanoma.
Rajanna S; Rastogi I; Wojdyla L; Furo H; Kulesza A; Lin L; Sheu B; Frakes M; Ivanovich M; Puri N
Anticancer Agents Med Chem; 2015; 15(7):856-68. PubMed ID: 25642982
[TBL] [Abstract][Full Text] [Related]
15. Design, Synthesis, and Evaluation of Small Molecule Gαq/11 Protein Inhibitors for the Treatment of Uveal Melanoma.
Ge Y; Shi S; Deng JJ; Chen XP; Song Z; Liu L; Lou L; Zhang X; Xiong XF
J Med Chem; 2021 Mar; 64(6):3131-3152. PubMed ID: 33715360
[TBL] [Abstract][Full Text] [Related]
16. Improving patient outcomes to targeted therapies in melanoma.
Eroglu Z; Smalley KS; Sondak VK
Expert Rev Anticancer Ther; 2016 Jun; 16(6):633-41. PubMed ID: 27137746
[TBL] [Abstract][Full Text] [Related]
17. The demethylating agent 5-Aza reduces the growth, invasiveness, and clonogenicity of uveal and cutaneous melanoma.
Rajaii F; Asnaghi L; Enke R; Merbs SL; Handa JT; Eberhart CG
Invest Ophthalmol Vis Sci; 2014 Aug; 55(10):6178-86. PubMed ID: 25146981
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic signaling in uveal melanoma.
Park JJ; Diefenbach RJ; Joshua AM; Kefford RF; Carlino MS; Rizos H
Pigment Cell Melanoma Res; 2018 Nov; 31(6):661-672. PubMed ID: 29738114
[TBL] [Abstract][Full Text] [Related]
19. Effects of Oncogenic Gα
Lapadula D; Farias E; Randolph CE; Purwin TJ; McGrath D; Charpentier TH; Zhang L; Wu S; Terai M; Sato T; Tall GG; Zhou N; Wedegaertner PB; Aplin AE; Aguirre-Ghiso J; Benovic JL
Mol Cancer Res; 2019 Apr; 17(4):963-973. PubMed ID: 30567972
[TBL] [Abstract][Full Text] [Related]
20. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
